Search clinical trials for: BYL719 and Olaparib

Total 272647 results

Dana-Farber Cancer Institute
Novartis; AstraZeneca

Completed

Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer

Breast Cancer | Ovarian Cancer

United States
Columbia University

Completed

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

Uveal Melanoma

United States
Novartis Pharmaceuticals

Completed

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

Advanced Solid Tumor

Japan
Novartis Pharmaceuticals

Available

Managed Access Program (MAP) to Provide Access to Alpelisib (BYL719) for Patients With PIK3CA-Related Overgrowth Spectrum (PROS)

PIK3CA-Related Overgrowth Spectrum (PROS)
Lawson Health Research Institute

Active, not recruiting

A Window of Opportunity Study to Assess the Modulation of Biomarkers in Head and Neck Squamous Cell Cancer (HNSCC) By Preoperative Treatment With BYL719

Head and Neck Squamous Cell Cancer

Canada
Peter MacCallum Cancer Centre, Australia
Novartis Pharmaceuticals

Completed

Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer (PIKNIC)

Metastatic Breast Cancer

Australia
Yonsei University

Unknown

An Open Label, Single Arm, Multicenter Phase II Study of BYL719 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck Who Failed to Respond to Platinum-based Therapy.

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Korea, Republic of
Novartis Pharmaceuticals

Terminated

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma

France, Taiwan, United States, Australia, Canada, Hong Kong, Singapore, Korea, Republic of, Netherlands
Novartis Pharmaceuticals

Active, not recruiting

Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1) (EPIK-P3)

PIK3CA-related Overgrowth Spectrum (PROS)

Spain, France, Ireland, United States
New Mexico Cancer Care Alliance

No longer available

Compassionate Use of BYL 719 Alpelisib

Lymphangioma

United States
Novartis Pharmaceuticals

Completed

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Relapsed and Refractory Multiple Myeloma

Italy, Germany, Singapore, Australia, United States
Array BioPharma

Completed

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

AML | Advanced and Selected Solid Tumors | High Risk and Very High Risk MDS

United States, Australia, Italy, Spain, France, Switzerland, United Kingdom
Novartis Pharmaceuticals

Completed

Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women

Breast Cancer

Canada, Italy, Czechia, United States, Belgium, Austria, Germany, Spain, Japan, Lebanon, Australia, Bulgaria, Israel, Netherlands, Colombia, Hong Kong, Brazil
Novartis Pharmaceuticals

Completed

PI3K Inhibitor BYL719 in Combination With the HSP90 Inhibitor AUY922 in Patients With Advanced or Metastatic Gastric Cancer

Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein

Taiwan, Switzerland, Korea, Republic of, Germany, United States, Japan
Novartis Pharmaceuticals

Recruiting

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. (EPIK-L1)

Lymphatic Malformations

Spain, France, Germany, Australia, United States
Novartis Pharmaceuticals

Available

Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer

HR+, HER2-, Advanced Breast Cancer
Memorial Sloan Kettering Cancer Center

Active, not recruiting

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer

United States
AstraZeneca
Merck Sharp & Dohme LLC; Iqvia Pty Ltd

Completed

A Study Using Olaparib Tablets for Subjects With Advanced Solid Tumours. (IVIVC)

Malignant Solid Tumor

Belgium
Murdoch Childrens Research Institute
Royal Children's Hospital; Peter MacCallum Cancer Centre, Australia

Not yet recruiting

A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations (TARGET-VM)

Arteriovenous Malformations | Vascular Malformations | MAP2K1 Gene Mutation | PIK3CA-related Overgrowth Spectrum | Vascular Anomalies | Lymphangioma | Lymphatic Malformation | KRAS G12D | Venous Malformation | Vascular Anomaly | KRAS G12C | PI3K Gene Mutation | Slow-Flow Vascular Malformation | Fast-Flow Vascular... and other conditions

Australia
Pfizer

Completed

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Colorectal Cancer

United States, Canada, Australia, Germany, Japan, Netherlands, Spain, France, Belgium, Korea, Republic of, Italy, Norway
Novartis Pharmaceuticals

Completed

A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients

3rd Line GIST

Italy, Belgium, Spain, Netherlands, Germany, United Kingdom, France, United States
Novartis Pharmaceuticals
NantCell, Inc.

Terminated

A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors

PIK3CA Mutated Advanced Solid Tumors | PIK3CA Amplified Advanced Solid Tumors

Spain, Belgium, United States, Canada
Novartis Pharmaceuticals

Completed

A Phase Ib Dose De-escalation Study With BYL719 in Premenopausal Patients With Locally Advanced or Metastatic Breast Cancer (B-YOND)

Pre-menopausal Breast Cancer | PI3K Pathway Inhibition

Taiwan, Hong Kong, Thailand, Korea, Republic of
CSPC Ouyi Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

Healthy Participants

China
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
Novartis Pharmaceuticals

Completed

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

France, Netherlands, Spain, Canada, Singapore, Germany, Korea, Republic of, Australia, Belgium, Switzerland, Italy, United States
University of Arizona
National Cancer Institute (NCI)

Terminated

Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

HPV Positive Oropharyngeal Squamous Cell Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | CDKN2A-p16 Positive | Stage I Oropharyngeal Squamous Cell Carcinoma AJCC V7 | Stage II Oropharyngeal Squamous Cell Carcinoma...

United States
University Health Network, Toronto
Novartis Pharmaceuticals

Completed

Phase I Study of BYL719 in Combination With Cisplatin and Radiotherapy in Patients With Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck | Locoregionally Advanced

Canada
Nordic Society of Gynaecological Oncology - Clinical...
Hellenic Cooperative Oncology Group; European Network of Gynaecological Oncological... and other collaborators

Recruiting

Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer (DOVACC)

Ovarian Cancer

Denmark
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT)

Completed

A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer. (OReO)

Epithelial Ovarian Cancer

Denmark, France, Germany, Italy, Spain, Poland, Belgium, Canada, United Kingdom, Israel, Norway
Centre Hospitalier Universitaire Dijon
Novartis Pharmaceuticals

Recruiting

Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP) (SESAM)

Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

France
Sandoz

Completed

A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With BRCA Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer

Breast Cancer | Ovarian Cancer

India
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Kura Oncology, Inc.

Recruiting

Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

HNSCC

United States
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
Qilu Pharmaceutical Co., Ltd.

Completed

Bioequivalence Study of Two Olaparib Tablets in Patients With Cancers

Neoplasms

China
Leiden University Medical Center
University Medical Center Groningen; Erasmus Medical Center

Recruiting

Functional Analysis of BRCAness (FAB)

BRCA1 Mutation | BRCA2 Mutation | Homologous Recombination Deficiency | Ovarian Neoplasm Epithelial

Netherlands
howard safran
Brown University; Lifespan; Novartis Pharmaceuticals Corporation (Financial supporter)

Terminated

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

Rectal Cancer

United States
National Cancer Institute, Naples

Recruiting

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study (MITO 31)

BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Italy
National Cancer Institute (NCI)

Recruiting

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Lung Neoplasms | Small Cell Lung Cancer | Prostate Cancer | Urothelial Carcinoma | Urothelial Cancer

United States
Sheba Medical Center

Completed

Efficacy and Safety of PARPi to Treat Pancreatic Cancer (10)

Pancreatic Cancer

Israel
AstraZeneca
Parexel

Approved for marketing

Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Ovarian Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Adenocarcinoma AJCC v7 | Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | Prostate Adenocarcinoma With Neuroendocrine...

United States
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Completed

Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO)

Recurrent Platinum Resistant Ovarian Cancer

United States
AstraZeneca

Completed

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

United States, Canada
AstraZeneca

Completed

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Colorectal Cancer

United States
Brown University
AstraZeneca; The Miriam Hospital; Rhode Island Hospital

Terminated

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes (337)

Prostate Cancer | Adenocarcinoma of the Prostate

United States
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

Trial of Olaparib in Combination With AZD5363 (ComPAKT) (ComPAKT)

Advanced Cancer

United Kingdom
AstraZeneca

No longer available

Olaparib Expanded Access Program for BRCA Mutated Platinum Sensitive Relapsed High Grade Epithelial Ovarian Cancer Patients in Japan

PSR Ovarian Cancer With a BRCA Mutation

Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States

Search clinical trials for: BYL719 and Olaparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritius

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations